FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053203772> ?p ?o ?g. }

• W2053203772 endingPage "S94" @default.
• W2053203772 startingPage "S87" @default.
• W2053203772 abstract "Enteropancreatic (EP) neuroendocrine carcinomas (NECs) represent relatively rare and heterogeneous malignancies. They are the most common group among neuroendocrine tumors (NETs). In most cases they are advanced at diagnosis and slow-growing, therefore conditioning a better prognosis compared with non neuroendocrine carcinomas from the same sites. No standard medical therapy exists, except for somatostatin analogs in functioning tumors, and octreotide LAR in functioning or non functioning well differentiated NECs from small bowel. Several systemic therapeutic options exist, including chemotherapy, somatostatin analog, interferon, peptide receptor radionuclide therapy (PRRT), and molecular targeted drugs. Among them some therapies have specific biological tumor targets and can be defined as “biological targeted therapies”. This review focuses on the status of EP NECs targeted therapies in the light of recent advances. Somatostatin receptors (SSTRs) are the first therapeutic target detected in EP NECs. Through them SS analogs and PRRT act, producing symptomatic, biochemical, and, to a lesser extent, antiproliferative effects. New SS analogs, covering a higher number of SSTR subtypes, were developed, including pasireotide (SOM230), which controls 25% of carcinoid syndromes resistant to full dose octreotide LAR. Chimeric analogs, which bind SSTR2/SSTR5 and dopamine-2 receptor subtype (D2), are in preclinical phase of development. Among the numerous molecular targeted agents investigated in NETs, mTOR inhibitors and VEGF/VEGFR/PDGFR inhibitors are in most advanced clinical phase of investigation. In particular, everolimus, sunitinib, and bevacizumab are all studied in phase III trials. Both everolimus and sunitinib produced significant survival benefit versus placebo in advanced progressing well-differentiated pancreatic NECs. Sunitinib data have been presented at the last ASCO in June 2010, and everolimus data will be presented at next ESMO in September 2010. Enteropancreatic (EP) neuroendocrine carcinomas (NECs) represent relatively rare and heterogeneous malignancies. They are the most common group among neuroendocrine tumors (NETs). In most cases they are advanced at diagnosis and slow-growing, therefore conditioning a better prognosis compared with non neuroendocrine carcinomas from the same sites. No standard medical therapy exists, except for somatostatin analogs in functioning tumors, and octreotide LAR in functioning or non functioning well differentiated NECs from small bowel. Several systemic therapeutic options exist, including chemotherapy, somatostatin analog, interferon, peptide receptor radionuclide therapy (PRRT), and molecular targeted drugs. Among them some therapies have specific biological tumor targets and can be defined as “biological targeted therapies”. This review focuses on the status of EP NECs targeted therapies in the light of recent advances. Somatostatin receptors (SSTRs) are the first therapeutic target detected in EP NECs. Through them SS analogs and PRRT act, producing symptomatic, biochemical, and, to a lesser extent, antiproliferative effects. New SS analogs, covering a higher number of SSTR subtypes, were developed, including pasireotide (SOM230), which controls 25% of carcinoid syndromes resistant to full dose octreotide LAR. Chimeric analogs, which bind SSTR2/SSTR5 and dopamine-2 receptor subtype (D2), are in preclinical phase of development. Among the numerous molecular targeted agents investigated in NETs, mTOR inhibitors and VEGF/VEGFR/PDGFR inhibitors are in most advanced clinical phase of investigation. In particular, everolimus, sunitinib, and bevacizumab are all studied in phase III trials. Both everolimus and sunitinib produced significant survival benefit versus placebo in advanced progressing well-differentiated pancreatic NECs. Sunitinib data have been presented at the last ASCO in June 2010, and everolimus data will be presented at next ESMO in September 2010." @default.
• W2053203772 created "2016-06-24" @default.
• W2053203772 creator A5020320888 @default.
• W2053203772 creator A5020435379 @default.
• W2053203772 creator A5022124014 @default.
• W2053203772 creator A5030038670 @default.
• W2053203772 creator A5039552697 @default.
• W2053203772 creator A5046559582 @default.
• W2053203772 creator A5049004748 @default.
• W2053203772 creator A5052353123 @default.
• W2053203772 creator A5064728742 @default.
• W2053203772 creator A5078823780 @default.
• W2053203772 creator A5079359965 @default.
• W2053203772 date "2010-11-01" @default.
• W2053203772 modified "2023-10-18" @default.
• W2053203772 title "Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas" @default.
• W2053203772 cites W1935825021 @default.
• W2053203772 cites W1963972672 @default.
• W2053203772 cites W1968641918 @default.
• W2053203772 cites W1969110841 @default.
• W2053203772 cites W1970617837 @default.
• W2053203772 cites W1970924175 @default.
• W2053203772 cites W1972486056 @default.
• W2053203772 cites W1977347411 @default.
• W2053203772 cites W1984292444 @default.
• W2053203772 cites W1985061998 @default.
• W2053203772 cites W1988106281 @default.
• W2053203772 cites W1988184140 @default.
• W2053203772 cites W1990509102 @default.
• W2053203772 cites W1993421446 @default.
• W2053203772 cites W1994118792 @default.
• W2053203772 cites W1998767852 @default.
• W2053203772 cites W2000841703 @default.
• W2053203772 cites W2012451298 @default.
• W2053203772 cites W2013239999 @default.
• W2053203772 cites W2018994090 @default.
• W2053203772 cites W2023901572 @default.
• W2053203772 cites W2026962476 @default.
• W2053203772 cites W2027867142 @default.
• W2053203772 cites W2031048655 @default.
• W2053203772 cites W2031301095 @default.
• W2053203772 cites W2031845215 @default.
• W2053203772 cites W2034404031 @default.
• W2053203772 cites W2034531422 @default.
• W2053203772 cites W2038629978 @default.
• W2053203772 cites W2039155298 @default.
• W2053203772 cites W2041357642 @default.
• W2053203772 cites W2050818286 @default.
• W2053203772 cites W2055212652 @default.
• W2053203772 cites W2056315084 @default.
• W2053203772 cites W2057103712 @default.
• W2053203772 cites W2059201573 @default.
• W2053203772 cites W2063178653 @default.
• W2053203772 cites W2065361341 @default.
• W2053203772 cites W2066161013 @default.
• W2053203772 cites W2067336143 @default.
• W2053203772 cites W2067874044 @default.
• W2053203772 cites W2068394756 @default.
• W2053203772 cites W2069387784 @default.
• W2053203772 cites W2072360771 @default.
• W2053203772 cites W2073355522 @default.
• W2053203772 cites W2074731710 @default.
• W2053203772 cites W2080232093 @default.
• W2053203772 cites W2087023042 @default.
• W2053203772 cites W2092047830 @default.
• W2053203772 cites W2092706522 @default.
• W2053203772 cites W2095317693 @default.
• W2053203772 cites W2098468148 @default.
• W2053203772 cites W2098482546 @default.
• W2053203772 cites W2106912357 @default.
• W2053203772 cites W2107436826 @default.
• W2053203772 cites W2110922803 @default.
• W2053203772 cites W2112064092 @default.
• W2053203772 cites W2112545770 @default.
• W2053203772 cites W2113788015 @default.
• W2053203772 cites W2118057643 @default.
• W2053203772 cites W2125398839 @default.
• W2053203772 cites W2125450370 @default.
• W2053203772 cites W2126783165 @default.
• W2053203772 cites W2128267006 @default.
• W2053203772 cites W2128544796 @default.
• W2053203772 cites W2135003342 @default.
• W2053203772 cites W2137142564 @default.
• W2053203772 cites W2140741951 @default.
• W2053203772 cites W2140978720 @default.
• W2053203772 cites W2141667495 @default.
• W2053203772 cites W2147448522 @default.
• W2053203772 cites W2149214723 @default.
• W2053203772 cites W2150784786 @default.
• W2053203772 cites W2153421801 @default.
• W2053203772 cites W2154883606 @default.
• W2053203772 cites W2157744078 @default.
• W2053203772 cites W2160531384 @default.
• W2053203772 cites W2166100060 @default.
• W2053203772 cites W2168906621 @default.
• W2053203772 cites W2188423024 @default.
• W2053203772 cites W2327663281 @default.
• W2053203772 cites W2410475467 @default.

• next